Richard Bright recognized the association of anemia and chronic renal disease in 1836 (1). Of all the various complications of end-stage renal failure (ESRDl, a normochromic normocytic anemia is the most common. It is nearly always present once the glomerular filtration rate falls to below 40% of normal (Fig. 1) ; indeed, the level of serum creatinine seems to be inversely proportional to the hematocrit (Fig. 2) (11) .
Pathogenesis of uremic anemia
In 1906, Carnot and Deflandre first postulated a humoral agent that controls erythrocyte production (2) . In 1957, Jacobsen et al identified the kidney as the major site of erythropoietin (EP) production and described the relation between oxygen tension and tissue oxygen demand (8) . Our current understanding of the production and actions of EP is summarized in Figure 3 (4) . Tissue hypoxia leads to the formation in the kidney of a labile erythropoietic factor. In the presence of plasma this becomes stable EP, a glycoprotein with molecular weight of about 39,000 daltons. The major target cell for EP in the bone marrow is a committed erythroid precursor called the Colony Forming Unit-Erythroid (CFU-E). EP increases the production of proerythroblasts and may also increase the release of reticulocytes from the bone marrow.
The mechanisms by which anemia develops in chronic renal failure are summarized in Figure 4 . The reduction in renal mass diminishes EP production, and falling glomerular filtration causes retention of toxic metabolic products which further depress erythroid proliferation and heme synthesis. These two processes lead to erythroid marrow hypoproliferation and decreased erythrocyte production. Other retained toxic metabolites have been postulated to cause defects in the coagulation cascade and to damage the red cell membrane, leading to a hemorrhagic diathesis and a decreased erythrocyte survival time. Both these processes will further the loss of ery-The International Journal Of Artificial Organs / Vol. g no. 4, 1986 / p.p. 199-206 throcytes and, together with decreased production, result in uremic anemia.
Other factors which may exacerbate uremic anemia Table I lists the factors that may exacerbate the anemia of ESRD. These factors can be divided into those decreasing erythropoiesis, those producing hemolysis and shortening erythrocyte survival, and those causing bleeding. They can be further subdivided into iatrongenic and non iatrogenic causes. Noniatrogenic causes of decreased erythropoiesis, other than reduced EP production, include iron deficiency, secondary hyperpreparathyroidism, infections, and malnutrition. Iatrogenic causes of decreased erythropoiesis include dialysis, which may induce deficiency of elements necessary for erythropoiesis through loss by diffusion into the dialysate or through blood left in the dialyzer, and bilateral nephrectomy, which removes the contribution of the diseased kidneys to EP production, leaving only extrarenal sites of production. These extra-renal sites in the liver and possibly the spleen do not usually produce enough EP to maintain the hematocrit above 20% and seem unresponsive to androgenic steroids. Among the numerous noniatrogenic causes of hemolysis and shortened erythrocyte survival are hypersplenism, autoimmune diseases, and secondary hyperparathyroidism. Iatrogenic factors include dialysis-related erythrocyte injury and drugs. Blood loss may occur through gastrointestinal hermorrhage, dialysis, or excessive blood sampling for diagnostic tests.
Laboratory features of uremic anemia
The laboratory features of the uncomplicated anemia of renal failure are shown in Table II . The sine qua non of this diagnosis is a normochromic normocytic anemia. 
General principals of the management of uremic anemia
An ESRD patient's sense of well being and his capacity for full activity and rehabilitation seem to correlate better with his hematocrit than with any other finding. Patients with higher hematocrits (i.e, greater than 25%) tend to feel better, experience less morbidity and are more active and productive than those with lower hematocrits. The anemia of ESRD is generally well-tolerated because of its ©byWichtig Editore, 1986 0391-3988/9000199-08 $02.00/0 Table I ), and are remarkably stable from month to month. Additional protection from the effects of anemia is afforded by acidemia and increased levels of 2,3-diphosphoglycerate (2,3-DPG) and adenosine triphosphate (ATP), which shift the oxyhemoglobin dissociation curve to the right ( Fig.  5 ), making the hemoglobin release its oxygen more readily to the tissues and be less completely saturated at any given level of oxygen tension. This phenomenon increases tissue oxygenation and suppresses EP production, thereby worsening the anemia of uremia. The hematocrit should be maintained at a level that affords the patient sufficient oxygen-carrying capacity to meet his individual physiological, functional, and psychosocial requirements. The (optimal> hematocrit is that which best meets the patient's needs and below which he may note symptoms of anemia: fatigue, decreased exercise tolerance, claudication, angina pectoris, congestive heart failure, adbominal angina, faintness, dizziness, syncope, hypotension, and malaise.
Those factors that seem most important in determining a patient's optimal hematocrit are his age, general health, psychological tolerance, and the condition of his cardiovascular, pulmonary and central nervous systems. A patient's tolerance of anemia also depends on his level of activity, concurrent illnesses, medications, fluid and electrolyte balance, and acid-base status. Certain general measures increase the hematocrits in most ESRD patients. The initiation of dialysis in a new ESRD patient is usually associated with a period of physiological and psychological adjustment which may last several months, during which the hematocrit spontaneously rises and feelings of fatigue and malaise lessen. Removal of excess extracellular fluid can only partially explain this phenomenon. Hypoxia during dialysis and rebound alkalosis after acetate-buffered dialysis may provide additional stimuli for EP production. Daily moderate exercise may increase the hematocrit, lower blood pressure, improve glucose tolerance, reduce serum triglyceride by 40%, and increase HDL-cholesterol by 20% (6) . If hypersplenism is documented by an erythrocyte survival time of less than 12 days and by splenic sequestration by 51Cr-tagged erythrocyte studies, splenectomy may reduce transfusion requirements dramatically. Changing from hemodialysis to peritoneal dialysis, intake of adequate protein and energy, providing thyroid replacement when necessary, and identification, avoidance, and treatment of any exacerbating factors (see Table I 
40%.
The bleeding tendency in uremia may be ameliorated inconsistently by dialysis and more reproducibly by giving cryoprecipitate (9) nally, any chronic inflammatory condition may lower both the serum iron and the iron-binding capacity. For these reasons, mean corpuscular volume and the serum ferritin level are more reliable indicators of the status of iron balance. In dialysis patients, because of their chronic illness, a serum ferritin level of 100 ng/ml or less may be indicative of iron deficiency (5, 15) . a level much higher than the lower limit of reference range used for the general population .
A normal 70-kg adult has approximately 4 g of iron; 2.5 g are incorporated in hemoglobin, 1.0 g is stored as ferritin or hemosiderin, and 30 mg circulates jn the blood bound to tranferrin. When the hemoglobin concentration is 15 g/dl, 1 ml of blood contains 0.5 mg of iron. The blood of an average dialysis patient, whose hemoglobin concentration is 10 g/dl, will contain 0.34 mg of iron per ml. The estimated blood loss per dialysis ranges from 2 to 10 ml. If we assume a blood loss of 10 ml per dialysis, or 30 ml per week, the patient will lose 10 mg of iron per week. Approximately 1 mg of iron is lost each day through non-dialysis routes. After six months of dialysis the amount of iron lost will be approximately 440 mg (183 mg non-dialysis plus 260 mg from dialysis).
Ferrous sulfate, given orally one or two hours after meals in a dose of 325 mg daily to three times a day, is usually sufficient to replenish iron stores and maintain optimal balance (5) . It should not be taken within two hours of a dose of aluminium hydroxide gel, as it binds to the iron and prevents its absorption. FeS04 may cause nausea, abdominal cramps, and constipation. Iron overload may result from excessive oral or parenteral iron or from transfusions. A serum ferritin level over 1000 ng/ml suggests hemochromatosis, which may affect liver, myocardium, and synovial surfaces. Deferoxamine chelation therapy may be required to remove excess iron. Deferoxamine chelation for aluminium-associated osteomalacia has been shown to raise the hematocrit (16) .
Administration of iron-dextran (Irnteron") has rarely been associated with major allergic reactions (anaphylaxis) since the dextran moiety was changed to make it less allergenic; however, as serious (non-fatal) systemic reactions have occurred in 11% of 481 non-dialysis patients treated with iron. dextran, caution is advised in administering this medication (7) . Its use can lead to a dramatic increase in erythropoiesis in iron-deficient ESRD patients who have been unable either to tolerate or to absorb oral iron supplements. Before giving the calculated dose of iron dextran, an intravenous test dose of 0.5 ml diluted in 50 ml physiologic saline is slowly infused post-dialysis. If there are no untoward reactions (flushing, nausea, vomiting, or hypotension) or allergic responses (urticaria, pruritus, or anaphylaxis) to the tests dose, then 2-20 rnl, diluted in 100-200 ml of normal saline, may be slowly in- nutes. The shortened bleeding time after infusion of DDAVP lasts about four hours and is associated with increased factor VIII coagulant activity, factor VIII-related antigen, ristocetin cofactor, and larger von Willebrandfactor multimers. Preoperative infusion of DDAVP will normalize the bleeding time and allow surgical procedures to be carried out without risk of hemorrhage.
When the general measures outlined above have been tried and exacerbating factors eliminated, the specific modalities of iron, folic acid, and histidine replacement, androgenic steroids, and transfusions may be used as follows: 1. Iron -Serum iron levels have a diurnal variation, the average concentrations being 110 ,ug/dl in the morning and 70 ,ug/dl in the evening. A low value drawn in the afternoon is suspected and should be repeated in the morning. The serum iron concentration will be raised for several hours after an oral dose of iron, even in the presence of significant iron deficiency; therefore, no oral iron should be taken within the 24 hours prior to drawing blood for a serum iron determination. Conditions that increase the turnover of erythrocytes (e.g., blood loss) will lower the serum iron concentration, and hemolysis and conditions that suppress erythropoiesis will raise it. Fi-fused.
Since an average dialysis patient loses approximately 400 mg of iron every six months and 10 ml of iron dextran contains 500 mg of iron, 1.5 of iron dextran per month, or 8 ml every six months, should be sufficient to replace iron losses.
Iron deficiency will cause anemia only after all of the iron stores have been depleted. To correct iron deficiency with iron dextran, it is necessary first to calculate the normal iron stores in mg, based on the patient's lean body mass (LBM) in kg.
.
LBM X 1000 Iron stores In mg = 70
This amount is divided by 50 to give the ml of iron dextran needed to replenish the iron stores. Next, to calculate the amount of iron dextran necessary to raise the hemoglobin to the desired concentration, subtract the measured hemoglobin concentration from the desired level and multiply by 3.4. Finally, add the two amounts and infuse intravenously in 2-ml aliquots weekly after or dialyses, as described above (7) .
For example, a 70-kg dialysis patient, documented to be iron deficient, has a hemoglobin of 7 g/dl. If we wish to raise his hemoglobin to 12 g/dl with iron dextran, we must first replenish his iron stores (1 g) with 20 ml (1000/50). To raise his hemoglobin 5 g/dl, we must give an additional 17 ml (5 x 3.4). The total dose of iron dextran will then be 37 rnl, which may be given in eighteen 2-ml aliquots.
2. Folic acid -In practice, folate deficiency is more of a theoretical than an actual hazard of dialysis, and frank megalocytic anemia due to folic acid deficiency caused by hemodialysis is rare. All dialysis patients should be screened for folate deficiency and receive a daily multiple vitamin preparation which includes the water-soluble vitamins and 1 mg folic acid.
3.
Histidine -If histidine levels are low, this essential amino acid may be given in a dose of 10 mg daily. This is probably unnecessary if dietary protein intake exceeds 1 g/kg/day.
4.
Anabolic androgenic steroids -Nandrolone decanoate (Dsca-durabolin'I is the most efficacious and least virilizing semisynthetic androgenic steroid and is the drug of choice (13) . Given for six months in doses of 3 mg/kg/ eek 1M post dialysis, by increasing the release of endogenous EPand directly stimulating committed stem cells, 204 it will effect a 5% or more rise in hematocrit in most ESRD patients. Individual response and tolerance to nandrolone is variable and may be due to differences in hepatic metabolism, end-organ responsiveness, or residual renal mass.
Undesiderable side effects of androgenic hormones include rare cholestatic jaundice, allergic reactions, exacerbation of prostatic cancer, priapism, arthralgia and arthritis, and, more commonly, personality changes (aggression, irritability, euphoria, hostility, or impulsiveness), excessive libido, loss of libido, impotence, prostatic hypertrophy, clitoral hypertrophy, acne, prurigo nodularis, male-pattern baldness, and increased facial, axillary and pubic hair. The virilizing side-effects and skin changes may be long-lasting or permanent despite discontinuation of the medication.
Anabolic steroids may impart a sense of heightened well-being and may increase appetite and cause rapid gains of tissue weight of 0.5 kg or more per week.
5.
Transfusions -Whether or not a transfusion is indicated will depend upon the relative severity of the anem ia, the rapidity and magnitude of the fall in hematocrit, the nature and magnitude of the symptoms, and the cause of the exacerbation of the anemia. Acute hemolysis or hemorrhage with a confirmed fall in the hematocrit to or below the patient's optimal hematocrit level usually requires transfusion. More chronic symptomatic anemia, unresponsive to other modalities of therapy, may also require transfusion. Pretransplant preparation protocols generally have required transfusion of six to ten units of packed erythrocytes within the six month period before transplantation (14) . If the patient is not symptomatically anemic, so much transfusion of erythrocytes is probably excessive, and buffy coat transfusions are preferable because the antigens promoting immune tolerance to foreign tissue are carried on the leukocytes.
There are few contraindications to transfusion, and these are only relative: previous sensitization to blood products with a history of leukopenic or febrile reactions to transfusions, mismatch of minor erythrocyte antigens, and a positive Coomb's test. Febrile and leukopenic reactions can generally be avoided by using leukocyte-poor packed cells and pre-tranfusion administration of oral acetaminophen and diphenhydramine hydrochloride and intravenous infusion of 150 mg hydrocortisone. Febrile transfusion reactions generally abate after a period of time and with repeated transfusions. Patients who refuse transfusions because of religious conviction should not be pressured to receive them.
Only packed erythrocytes, not whole blood, should be transfused in order to minimize the fluid load and avoid the acquisition of unneeded blood products. The blood should be infused during dialysis to allow removal of the excessive fluid volume and potassium. Transfusions should be limited to the minimum amount necessary to raise the hematocrit to the desired level. Three ml of packed cells per kg of body weight will raise the hemoglobin concentration by 1 g/dl (12) .
It is generally unnecessary to give frozen, washed or leukocyte-poor packed cells; this only adds to the expense of transfusion and does not protect against either transmissible infectious agents or sensitization to leukocyte antigens. All ESRD patients treated in a hemodialysis center should be screened monthly for acute hepatitis with determination of transaminases; and the nonimmune patients (anti-HBs and HBsAg-negative), for hepatitis B surface antigen (HBsAg). All nonimmune patients and staff should also be immunized with hepatitis B vaccine (Heptavax"),
The hazards of transfusion are: sensitization to blood products; receiving mismatched blood with resultant hemolysis; febrile and leukopenic reactions; transmission of infectious agents such as non-A, non-B hepatitis virustes), hepatitis B virus, cytomegalovirus, Epstein-Barr virus, toxoplasmosis, and the agent which causes Acquired Immunodeficiency Syndrome; the iron overload; volume overload; and hyperkalemia. It is therefore best to avoid transfusions whenever possible and to transfuse only for specific reasons when no other modality of therapy is effective.
6. Exogenous erythropoietin -Currently unavailable, exogeneous erythropoietin produced by recombinat DNA technology will probably be widely used in ESRD patients if shown to be safe, effective, and inexpensive.
In general, whenever the hematocrit falls to or below 20% the patients should receive one or more of the specific modalities of therapy, short of transfusion, in order to prevent further fall in hematocrit to below his optimal hemotocrit. If the hematocrit falls rapidly or the patient becomes significantly symptomatic, transfusion must be employed while searching for remediable causes of anemia and employing other modalities of therapy.
